Correlation Between Mineralys Therapeutics and Gilead Sciences

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics and Gilead Sciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics and Gilead Sciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics Common and Gilead Sciences, you can compare the effects of market volatilities on Mineralys Therapeutics and Gilead Sciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics with a short position of Gilead Sciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics and Gilead Sciences.

Diversification Opportunities for Mineralys Therapeutics and Gilead Sciences

0.3

Correlation Coefficient

Mineralys Therapeutics  Gilead Sciences

Weak diversification

The 3 months correlation between Mineralys and Gilead is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics Common and Gilead Sciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Gilead Sciences and Mineralys Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics Common are associated (or correlated) with Gilead Sciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gilead Sciences has no effect on the direction of Mineralys Therapeutics i.e., Mineralys Therapeutics and Gilead Sciences go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics and Gilead Sciences

Given the investment horizon of 90 days Mineralys Therapeutics Common is expected to generate 3.88 times more return on investment than Gilead Sciences. However, Mineralys Therapeutics is 3.88 times more volatile than Gilead Sciences. It trades about 0.01 of its potential returns per unit of risk. Gilead Sciences is currently generating about -0.33 per unit of risk. If you would invest  1,299  in Mineralys Therapeutics Common on February 5, 2024 and sell it today you would lose (4.00) from holding Mineralys Therapeutics Common or give up 0.31% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics Common  vs.  Gilead Sciences

Mineralys Therapeutics

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Mineralys Therapeutics may actually be approaching a critical reversion point that can send shares even higher in June 2024.

Gilead Sciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Gilead Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in June 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Mineralys Therapeutics and Gilead Sciences

The main advantage of trading using opposite Mineralys Therapeutics and Gilead Sciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics position performs unexpectedly, Gilead Sciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gilead Sciences will offset losses from the drop in Gilead Sciences' long position.

The idea behind Mineralys Therapeutics Common and Gilead Sciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.